Search
Practical information
When do the meetings take place?
CRTH 2025 timeline is as follows:
Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.
SWG Committee
Current committee members
Konstanze Döhner, Germany (Chair (EHA Board member))
Dominique Bonnet, France (Vice-Chair)
Immacolata Andolfo, Italy
Igor Aurer, Croatia
Raul Cordoba, Spain
Hermann Einsele, Germany
Eleni Gavriilaki, Greece (Representative, Young EHA Committee)
Kirsten Gronbaek, Denmark (EHA Board)
Esther Oliva, Italy
Marc Raaijmakers, The Netherlands
Josef Vormoor, The Netherlands
Aim
The SWG Committee…
EHA-AHA Hematology Tutorial On Lymphoid Malignancies Attracts International Audience
EHA-AHA Hematology Tutorial on Lymphoid Malignancies
October 18-20, 2019 | Yerevan, Armenia
Meeting chairs:
Prof G Gaidano (European Hematology Association)
Prof Y Hakobyan (Armenian Hematology Association)
Prof S Danielyan (Haematology center after Prof. R. H.
Challenges and opportunities in the diagnostics and management of onco-hematological patients under the microscope during tutorial in Russia
Onco-hematology was the focus of the two-day EHA Hematology Tutorial in Moscow, Russia, the third joint tutorial organized by EHA, the National Hematological Society (NHS) and the Russian-Oncohematology Society (ROHS).
Read moreMission ‘Gene Therapy’ for Horizon Europe
Mission ‘Gene Therapy’ for Horizon Europe
Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.
Registration & accommodation
Register here
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.
EHA in the BioMed Alliance: joining forces for biomedical research
At a recent meeting at the European Parliament, Prof.
Read moreRestoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab
Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- »